Arcturus Therapeutics Holdings Inc. ARCT
8.31 USD -0.05 (-0.60%)
Regular-session close
8.31 0.00 0.00%
After hours · Nov 16, 4:01 PM ET
8.27 Day range 9.78
5.50 52-week range 17.96
- YTD
- +35.56%
- 1 year
- +14.31%
News
businesswire.com Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
seekingalpha.com Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript
marketbeat.com What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call Arcturus Therapeutics NASDAQ: ARCT expects to complete enrollment in a mid-stage cystic fibrosis study by the end of 2026 and begin dosing a next-generation treatment for a rare liver disorder in the…
zacks.com Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.49 per share a year ago.
benzinga.com Arcturus Therapeutics Q3 2026 Earnings Call Transcript Arcturus Therapeutics (NASDAQ:ARCT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Arcturus Therapeutics Q3 EPS $(0.26) Beats $(0.68) Estimate, Sales $18.297M Beat $7.998M Estimate Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.68) by 61.76 percent. This is a 46.94 percent increase over losses…
businesswire.com Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
businesswire.com Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026 SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
zacks.com 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
marketbeat.com Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to…
seekingalpha.com Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
businesswire.com Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
seekingalpha.com Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-term catalyst and ARCT-032 for cystic fibrosis in phase 2. ARCT-810 has shown promising phase 2…
gurufocus.com Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform Arcturus Therapeutics Holdings Inc. (the âCompanyâ, âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and
businesswire.com Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
seekingalpha.com Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
defenseworld.net 56,895 Shares in Arcturus Therapeutics Holdings Inc. $ARCT Bought by Hsbc Holdings PLC Hsbc Holdings PLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) during the second quarter, according to the company in its most recent 13F filing with the…
defenseworld.net BlackRock Inc. Invests $17.57 Million in Arcturus Therapeutics Holdings Inc. $ARCT BlackRock Inc. bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The…
businesswire.com Arcturus Therapeutics to Participate in Upcoming Investor Conferences SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
zacks.com Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which…
marketbeat.com Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is…
seekingalpha.com Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
